Novo Nordisk A/S's stock has taken a hit as its semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – surprisingly missed consensus in the second quarter but the Danish drugmaker is emphasising the significant volume growth and demand for the products which is not going to dry up anytime soon.
Novo Nordisk Not Unnerved By ‘Quarterly Blip’
Sales of Wegovy and Ozempic were strong again in the second quarter and while they were shy of analyst expectations, the Copenhagen-based giant is confident of continuing demand despite competition from Eli Lilly’s Zepbound.
